Print

Ariad Pharmaceuticals, Inc. (ARIA) Announces 12-Month Data from Pivotal PACE Trial of Ponatinib in Heavily Pretreated Patients With Advanced-Phase CML and Ph+ ALL  
12/11/2012 10:26:57 AM

ATLANTA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced twelve-month follow-up data from the pivotal PACE trial of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with advanced forms of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that 57 percent of accelerated-phase CML patients in the trial, including 50 percent of patients with the T315I mutation, achieved a major hematologic response (MaHR), the primary end-point for patients with advanced disease in the trial.
//-->